Murine iPSC-Loaded Scaffold Grafts Improve Bone Regeneration in Critical-Size Bone Defects

Franziska Kessler,Kevin Arnke,Benjamin Eggerschwiler,Yvonne Neldner,Sonja Märsmann,Olivier Gröninger,Elisa A. Casanova,Fabienne A. Weber,Matthias A. König,Wendelin J. Stark,Hans-Christoph Pape,Paolo Cinelli,Simon Tiziani

DOI: https://doi.org/10.3390/ijms25105555

IF: 5.6

2024-05-21

International Journal of Molecular Sciences

Abstract:In certain situations, bones do not heal completely after fracturing. One of these situations is a critical-size bone defect where the bone cannot heal spontaneously. In such a case, complex fracture treatment over a long period of time is required, which carries a relevant risk of complications. The common methods used, such as autologous and allogeneic grafts, do not always lead to successful treatment results. Current approaches to increasing bone formation to bridge the gap include the application of stem cells on the fracture side. While most studies investigated the use of mesenchymal stromal cells, less evidence exists about induced pluripotent stem cells (iPSC). In this study, we investigated the potential of mouse iPSC-loaded scaffolds and decellularized scaffolds containing extracellular matrix from iPSCs for treating critical-size bone defects in a mouse model. In vitro differentiation followed by Alizarin Red staining and quantitative reverse transcription polymerase chain reaction confirmed the osteogenic differentiation potential of the iPSCs lines. Subsequently, an in vivo trial using a mouse model (n = 12) for critical-size bone defect was conducted, in which a PLGA/aCaP osteoconductive scaffold was transplanted into the bone defect for 9 weeks. Three groups (each n = 4) were defined as (1) osteoconductive scaffold only (control), (2) iPSC-derived extracellular matrix seeded on a scaffold and (3) iPSC seeded on a scaffold. Micro-CT and histological analysis show that iPSCs grafted onto an osteoconductive scaffold followed by induction of osteogenic differentiation resulted in significantly higher bone volume 9 weeks after implantation than an osteoconductive scaffold alone. Transplantation of iPSC-seeded PLGA/aCaP scaffolds may improve bone regeneration in critical-size bone defects in mice.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the treatment dilemma of "critical - size bone defects" encountered clinically. Specifically, when bones cannot heal on their own after a fracture, especially in the presence of large bone defects, complex long - term treatment is required, and this treatment is accompanied by a high risk of complications. Current methods for treating such bone defects, such as autologous bone grafts and allogeneic bone grafts, do not always achieve successful results. Therefore, researchers have explored the possibility of using stem cell therapy to promote bone regeneration, especially by using induced pluripotent stem cells (iPSCs).

In this study, the researchers specifically explored two methods: one was to directly load mouse iPSCs onto porous poly(lactic - co - glycolic acid)/amorphous calcium phosphate (PLGA/aCaP) scaffolds; the other was to use the extracellular matrix (ECM) extracted from iPSCs and load it onto the same scaffolds to treat critical - size bone defects in a mouse model. Through these experiments, the study aimed to evaluate the potential of iPSCs and their - derived ECM in promoting bone regeneration, especially when compared with traditional treatment methods. The results of the study showed that the scaffolds loaded with iPSCs were significantly better than those using only scaffolds or scaffolds loaded with iPSCs - ECM in promoting new bone formation. This provides important scientific basis for the future development of more effective treatment strategies for bone defects.